Company Summary

About Nanospectra Biosciences

Nanospectra Biosciences is a private company founded in 2002. Nanospectra has an exclusive license from Rice University to eleven issued US patents related to nanoshells and related commercial uses of these and other nanoparticles. While there are numerous therapeutic, diagnostic, and industrial commercial applications, Nanospectra is focused on the development of AuroLase® Therapy utilizing AuroShell® Particles (also referred to as nanoshells) for the precise, particle-based thermal ablation of solid tumors.

Nanospectra commenced formal operations in 2002 to commercialize these applications. Nanospectra has an open Investigational Device Exemption (IDE) wtih the U.S. FDA to evaluate the safety and efficacy of AuroLase Therapy for the treatment of refractory or recurrent head and neck cancers. The use of AuroLase Therapy in other cancer types is under development.

Nanoshells were developed in the laboratories of Naomi Halas, PhD, and Stanley C. Moore, Professor in Electrical and Computer Engineering and Professor of physics, chemistry, and Biomedical engineering at Rice University, in the 1990’s. In collaboration with Jennifer West, PhD, and Isabel C. Cameron, Professor and Chair of Bioengineering of Rice University, a series of life science applications were envisioned which led to the formation of Nanospectra. Drs. Halas and West were named Inventors of the Year by the Texas Bar Assocation for one of their numerous patents licensed to Nanospectra.

Technology Developed by Leading Scientists

In addition to the work of our founding scientists, other leading scientists contributed to the development of our technology and product applications.  Several of the collaborators who have made significant contributions to our success include:

Rinat Esenaliev, PhD., Professor, Director of Laboratory for Optical Sensing and Monitoring, Center for Biomedical Engineering, UTMB Cancer Center, Department of Neuroscience and Cell Biology, and Department of Anesthesiology, University of Texas Medical Branch.  Dr. Esenaliev performed pioneering work in the use of electromagnetic radiation and particle-assisted therapies for the treatment of cancer.  Nanospectra has a license to Dr. Eseanliev’s early patent in this area.

John Hazle, PhD, FAAPM, Professor, Department of Imaging Physics, Division of Diagnostic Imaging, The University of Texas M. D. Anderson Cancer Center.  Dr. Hazle collaborated with our founders and performed the initial thermal profiling in vivo studies of our technology, and he has led the development of several imaged guided and feedback applications of our therapy.

We have been awarded peer-reviewed federal grants and awards exceeding $8 million to develop AuroShell particles for the diagnosis and treatment of cancer and for other diagnostic and commercial applications. Additional funding in excess of $6 million has been raised from angel investors, private investment funds, and the Texas State Emerging Technology Fund.

Milestones

  • 2002: Commenced operations, license from Rice University
  • 2003: Successful demonstration of in vivo efficacy in animals
  • 2004: Received Advanced Technology Program award of $2 million; advanced devlopment of manufacturing
  • 2006: Received Texas merging Technology Fund award of $1.25 illion; completed cGMP manufacturing facility
  • 2007: Completed animal and laboratory toxicity/safety tests
  • 2008: Received IDE and initiated human clinical trial study for use of AuroLase™ Therapy for refractory/recurrent head and neck cancer
  • 2010: Completed 8 subjects in the head and neck clinical trial
  • 2011: Initiated a pilot study of AuroLase™ Therapy for primary prostate cancer (Mexico)
  • 2012: Treated final subject in prostate cancer pilot study (Mexico); trail completed Q1 2013
  • 2012: Received IDE and initiated human clinical trial study for use of AuroLase™ Therapy for primary and/or metastatic lung tumors

AuroLase AuroShell Particle - About Us

 

Management

David Jorden
CEO
Mr. Jorden has been appointed to serve as Interim CEO with Nanospectra effective June 1, 2013.  He has extensive executive experience which includes currently serving as Executive Chairman and Executive Board Member for Cytomedix, Inc. and previously serving as Acting Chief Financial Officer for Opexa Therapeutics, Inc., Vice President of Wealth Management for Morgan Stanley, Vice President and Chief Financial Officer for Genometrix, Inc., and Principal for Fayez Sarofim & Co.  Mr. Jorden currently serves as the Director of Cytomedix, Inc., Opexa Therapeutics, Inc., PLx Pharma, Inc., and Nanospectra Biosciences Inc.  He holds the Chartered Financial Analyst and Certified Public Accountant designations and has extensive experience in various aspects of corporate finance and accounting for public companies including capital formation and deployment.  He holds a MBA from Kellogg School of Management at Northwestern University and a BBA from the University of Texas/Austin.

Glenn P. Goodrich, PhD
COO & Vice President, Process Development and Chemistry
Dr. Goodrich has been with Nanospectra since 2005.  He holds a BS in Chemistry and a BA in Computer Science from The University of Iowa and a PhD in Chemistry from Penn State University.  He has extensive experience with fabrication and application of nanoparticles, having worked in the field in graduate school and as a post-doctoral fellow under Dr. Naomi Halas at Rice University.

Jon Schwartz, PhD
Director, Clinical Research
Dr. Schwartz has been with Nanospectra since 2005.  He holds a BS and a MS in Electrical Engineering from Rice Universtiy and a PhD in Biophysics from The University of Texas Graduate School of Biomedical Science.  He is responsible for the conduct of Nanospectra’s clinical pilot studies for the treatment of human cancers.  Dr. Schwartz’ primary area of research is the development of minimally-invasive tumor ablation techniques using nanoparticles as a means of improving the discrimination between tumor and normal tissue.

Naomi Halas, PhD
Co-Founder
Professor, Rice University
Dr. Halas is the Stanley C. Moore Professor of Electrical and Computer Engineering at Rice University.  She is author of more than 200 refereed publications, has more than ten issued patents, and has presented more than 300 invited talks.  She is known as the inventor of nanoparticles with tunable optical properties controlled by their shape and structure.  She pursues fundamental studies of light-nanoparticle interactions that give rise to new properties and effects, leading to useful applications in biomedicine, chemical sensing, and energy.  She is a Member of the American Academy of Arts and Sciences and a Fellow of the American Physical Society, the Optical Society of America, the International Society for Optical Engineering (SPIE), the Institute for Electrical and Electronics Engineers, and the American Association for the Advancement of Science.

 

 

Board of Directors

Patrick W. Pace, MD
Chairman of the Board of Directors
Dr. Pace has been on the Board of Directors for Nanospectra since April 2010.  His background includes almost 10 years of financial experience in healthcare.  He currently serves as a Managing Director at Citadel Securities.  Previously, he invested in healthcare for AIG Investments and covered the medical device sector as a Senior Analyst for UBS.  He holds an MD from The University of Texas Medical School – Houston and a BA (Honors in Psychology) from Vanderbilt University.

David Jorden
Director
Mr. Jorden has been appointed to serve as Interim CEO with Nanospectra effective June 1, 2013.  He has extensive executive experience which includes currently serving as Executive Chairman and Executive Board Member for Cytomedix, Inc. and previously serving as Acting Chief Financial Officer for Opexa Therapeutics, Inc., Vice President of Wealth Management for Morgan Stanley, Vice President and Chief Financial Officer for Genometrix, Inc., and Principal for Fayez Sarofim & Co.  Mr. Jorden currently serves as the Director of Cytomedix, Inc., Opexa Therapeutics, Inc., PLx Pharma, Inc., and Nanospectra Biosciences Inc.  He holds the Chartered Financial Analyst and Certified Public Accountant designations and has extensive experience in various aspects of corporate finance and accounting for public companies including capital formation and deployment.  He holds a MBA from Kellogg School of Management at Northwestern University and a BBA from the University of Texas/Austin.

David Bristol
Director
David Bristol currently serves as an Officer and Director of HCF Enterprises, Inc., a privately held family business responsible for family office operations and investment management in public and private securities, real estate and oil and gas.  He is also a Senior VP and Director of Sentinel Trust Company, LBA, a private trust company serving high net worth clients.  Mr. Bristol has held both of these positions since 1996.  Prior to that, Mr. Bristol had 8 years experience in petroleum exploration and software technology.

Brad Nyberg
Director 
Brad Nyberg is Co-Founder of Scarlet Fire Private Investment, LP in Houston, TX and is currently on the Board of Directors at ACS Athletics, Inc. Since 2005 the partnership has been making equity and debt investments in IT, software and bioscience companies in both Texas and Colorado. Brad and his wife, Anne Loo, were part of the investment group that lead the funding of IZZE Soda Company (Boulder, CO) which was sold to Pepsi in 2008 and investors in Phurnace Software (Sold to BMC Software 2010). They are currently also partners in Briargate (Colorado Springs), one of the largest residential developments in Colorado.  Scarlet Fire’s current investments include Glycos Biotechnologies, Quarri Technologies Inc., Graphicly Inc., ACS Athletics, DNAtrix, Inc., Surge Accelerator, Nanospectra Biosciences Inc., Mercury Fund I and III. Prior to Scarlet Fire, Brad worked for both Fleet Bank and MGIC Investment Corp (MTG) and holds B.S. in Finance from the University of Wisconsin-LaCrosse.

Blair Shamel
Director 
Blair Shamel has focused on the business of cancer since launching the Prostate Specific Antigen test for Hybritech Incorporated in the mid-1980s. Under his leadership the test became well known to virtually all men over 50 and grew to a market of several hundred million dollars.   His career has included executive leadership positions or strategic consulting assignments in diagnostic, device and therapeutic companies, with a strong emphasis on prostate cancer. A partial list of companies’ technologies includes several novel molecular diagnostic tests, advanced imaging technologies, implantable devices for the treatment of prostate cancer, and novel biomarkers for myeloma and lung cancer.  Most recently he served as CEO for SNP Bio, a start-up phase company developing a novel gene signature for predicting the development of prostate cancer.  His expertise includes go-to-market strategy development, market and business research, clinical strategy, project management, technology acquisition and out-licensing, market development, KOL development and expert analysis of business opportunities in the cancer and other high-value markets. Blair earned a BS in Biology from Rhodes College and a MS in Pharmacology from Emory University. He is an Affiliate Member of the American Urology Association and the European Association for Urology.  He has served on the Board of Directors of H37 Inc., SNP Bio and several non-profit organizations.